Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to $85.4 billion.

  • Astrazeneca's Non-Current Assets rose 913.33% to $85.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $85.4 billion, marking a year-over-year increase of 913.33%. This contributed to the annual value of $85.4 billion for FY2025, which is 913.33% up from last year.
  • Latest data reveals that Astrazeneca reported Non-Current Assets of $85.4 billion as of Q4 2025, which was up 913.33% from $84.5 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Non-Current Assets ranged from a high of $85.4 billion in Q4 2025 and a low of $46.2 billion during Q1 2021
  • In the last 5 years, Astrazeneca's Non-Current Assets had a median value of $77.2 billion in 2022 and averaged $75.0 billion.
  • In the last 5 years, Astrazeneca's Non-Current Assets surged by 11860.02% in 2021 and then crashed by 815.72% in 2022.
  • Over the past 5 years, Astrazeneca's Non-Current Assets (Quarter) stood at $79.1 billion in 2021, then dropped by 6.61% to $73.9 billion in 2022, then grew by 2.94% to $76.1 billion in 2023, then grew by 2.82% to $78.2 billion in 2024, then increased by 9.13% to $85.4 billion in 2025.
  • Its last three reported values are $85.4 billion in Q4 2025, $84.5 billion for Q3 2025, and $83.5 billion during Q2 2025.